MARKET

BMRN

BMRN

BioMarin Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

81.76
-1.56
-1.87%
After Hours: 78.80 -2.96 -3.62% 19:56 02/25 EST
OPEN
83.38
PREV CLOSE
83.32
HIGH
83.95
LOW
81.35
VOLUME
1.53M
TURNOVER
--
52 WEEK HIGH
131.95
52 WEEK LOW
68.25
MARKET CAP
14.84B
P/E (TTM)
18.89
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-BioMarin Reports Q4 And Full-Year 2020 Financial Results
reuters.com · 6h ago
BioMarin Pharmaceutical EPS beats by $0.29, beats on revenue
BioMarin Pharmaceutical (BMRN): Q4 GAAP EPS of $0.12 beats by $0.29.Revenue of $452.1M (-0.5% Y/Y) beats by $11.96M.As of December 31, 2020, BioMarin had cash, cash equivalents and investments totaling $1.35B.Press
Seekingalpha · 9h ago
BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates
, Feb. 25, 2021 /PRNewswire/ --
PR Newswire - PRF · 9h ago
Biomarin Pharmaceutical Q4 EPS $0.12 Beats $(0.19) Estimate, Sales $452.10M Beat $440.23M Estimate
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $(0.19) by 163.16 percent. This is a 50 percent increase over earnings of $0.08 per share
Benzinga · 9h ago
BioMarin Pharmaceutical, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 10h ago
BioMarin Pharmaceutical Reports Mixed Q4 Results; Sets 2021 Revenue Outlook
MT Newswires · 13h ago
-- Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q4 Revenue $452.1M
MT Newswires · 13h ago
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 17h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BMRN. Analyze the recent business situations of BioMarin Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BMRN stock price target is 110.95 with a high estimate of 188.00 and a low estimate of 84.00.
EPS
Institutional Holdings
Institutions: 827
Institutional Holdings: 193.71M
% Owned: 106.71%
Shares Outstanding: 181.53M
TypeInstitutionsShares
Increased
185
11.40M
New
136
517.00K
Decreased
165
9.01M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.83%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Chief Executive Officer/Director
Jean-Jacques Bienaime
Chief Financial Officer/Executive Vice President
Brian Mueller
Corporate Executive
Henry Fuchs
Executive Vice President/Chief Technology Officer
C. Greg Guyer
Executive Vice President/General Counsel/Secretary
G. Eric Davis
Executive Vice President
Jeff Ajer
Chief Accounting Officer/Vice President
Andrea Acosta
Chief Scientific Officer
Lon Cardon
Lead Director/Independent Director
Richard Meier
Director
Liz Anderson
Director
Maykin Ho
Independent Director
Elizabeth Anderson
Independent Director
Willard Dere
Independent Director
Michael Grey
Independent Director
Elaine Heron
Independent Director
Robert Hombach
Independent Director
V. Bryan Lawlis
Independent Director
Alan Lewis
Independent Director
David Pyott
Independent Director
Dennis Slamon
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About BMRN
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Webull offers kinds of BioMarin Pharmaceutical Inc. stock information, including NASDAQ:BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.